Cero Therapeutics Holdings Inc (CERO)

$8.74 +0.74 (9.25%)
Market Cap 3.09M
Revenue (ttm) 0.00
Net Income (ttm) -8.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 67,265
Avg Vol 1,382,060
Day's Range N/A - N/A
Shares Out 386,000.00
Stochastic %K 70%
Beta 0.46
Analysts Strong Sell
Price Target $30.00

Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 407-2376
Address:
201 Haskins Way, Suite 230, South San Francisco, United States
tickertales
tickertales Aug. 18 at 6:05 PM
$CERO 📈👀
0 · Reply
TommyShelbyOBE
TommyShelbyOBE Aug. 18 at 5:55 PM
$CERO $SPY $SPX Always winning and PAYtience PAYS😎🤌
0 · Reply
ChipPetey11
ChipPetey11 Aug. 18 at 5:05 PM
$CERO
0 · Reply
transamlover
transamlover Aug. 18 at 10:37 AM
$CERO
0 · Reply
Washingtonstate
Washingtonstate Aug. 15 at 12:33 PM
$CERO something is happening here… 😁
0 · Reply
BigDollarGains
BigDollarGains Aug. 13 at 6:23 PM
$CERO CEROW warrant way cheap at .015. Warrant is only 1 and half penny Stock at $8.15
0 · Reply
Staunker
Staunker Aug. 13 at 5:54 PM
$CERO the first part of phase one was a 28 day observation period. part two should be about three weeks in. assuming it is also a 28 day period I expect some updates in a couple weeks. i look forward to some updates and with orphan status hopefully they get right in to setting up for phase 2!
0 · Reply
Washingtonstate
Washingtonstate Aug. 13 at 4:37 PM
$CERO winner !
0 · Reply
Ultra_Calls
Ultra_Calls Aug. 13 at 3:20 PM
$CERO $8.00 gearing up for another run to $20+ like we did on 6/17!!! Check that chart gap fill 🔥 $BSLK & $WBTN up huge today - trend list
0 · Reply
Pharaon_Cr
Pharaon_Cr Aug. 13 at 9:21 AM
$CERO
0 · Reply
Latest News on CERO
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Jul 31, 2025, 8:10 AM EDT - 18 days ago

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

Jul 8, 2025, 12:00 AM EDT - 5 weeks ago

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

Jun 23, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

Jun 17, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

Jun 11, 2025, 9:10 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

Jun 6, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

Jun 2, 2025, 9:05 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

May 30, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

May 8, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 30, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 25, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 24, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

Apr 22, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

Apr 10, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 9, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

Mar 31, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

Mar 27, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Mar 19, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

Mar 13, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

Mar 6, 2025, 8:15 AM EST - 5 months ago

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

Mar 5, 2025, 8:15 AM EST - 5 months ago

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

Feb 6, 2025, 8:15 AM EST - 6 months ago

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Feb 5, 2025, 8:00 PM EST - 6 months ago

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

Dec 6, 2024, 9:00 AM EST - 9 months ago

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Nov 15, 2024, 8:45 AM EST - 9 months ago

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Nov 11, 2024, 8:15 AM EST - 10 months ago

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Provides Corporate Update

Oct 21, 2024, 9:00 AM EDT - 10 months ago

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Oct 2, 2024, 9:15 AM EDT - 11 months ago

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

Sep 25, 2024, 2:49 PM EDT - 11 months ago

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Sep 25, 2024, 9:17 AM EDT - 11 months ago

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Jul 18, 2024, 7:55 AM EDT - 1 year ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

ASLN

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Jun 13, 2024, 8:15 AM EDT - 1 year ago

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

May 15, 2024, 8:00 AM EDT - 1 year ago

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Mar 7, 2024, 7:00 AM EST - 1 year ago

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

Feb 14, 2024, 4:48 PM EST - 1 year ago

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Jun 5, 2023, 8:00 AM EDT - 2 years ago

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Dec 6, 2022, 9:18 PM EST - 2 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders

tickertales
tickertales Aug. 18 at 6:05 PM
$CERO 📈👀
0 · Reply
TommyShelbyOBE
TommyShelbyOBE Aug. 18 at 5:55 PM
$CERO $SPY $SPX Always winning and PAYtience PAYS😎🤌
0 · Reply
ChipPetey11
ChipPetey11 Aug. 18 at 5:05 PM
$CERO
0 · Reply
transamlover
transamlover Aug. 18 at 10:37 AM
$CERO
0 · Reply
Washingtonstate
Washingtonstate Aug. 15 at 12:33 PM
$CERO something is happening here… 😁
0 · Reply
BigDollarGains
BigDollarGains Aug. 13 at 6:23 PM
$CERO CEROW warrant way cheap at .015. Warrant is only 1 and half penny Stock at $8.15
0 · Reply
Staunker
Staunker Aug. 13 at 5:54 PM
$CERO the first part of phase one was a 28 day observation period. part two should be about three weeks in. assuming it is also a 28 day period I expect some updates in a couple weeks. i look forward to some updates and with orphan status hopefully they get right in to setting up for phase 2!
0 · Reply
Washingtonstate
Washingtonstate Aug. 13 at 4:37 PM
$CERO winner !
0 · Reply
Ultra_Calls
Ultra_Calls Aug. 13 at 3:20 PM
$CERO $8.00 gearing up for another run to $20+ like we did on 6/17!!! Check that chart gap fill 🔥 $BSLK & $WBTN up huge today - trend list
0 · Reply
Pharaon_Cr
Pharaon_Cr Aug. 13 at 9:21 AM
$CERO
0 · Reply
woolpourpis69
woolpourpis69 Aug. 11 at 11:56 AM
$CERO clown shit
1 · Reply
Pharaon_Cr
Pharaon_Cr Aug. 11 at 9:04 AM
$ENLV LFG ! Green week ahead!! $BTAI $TNXP $CERO
0 · Reply
StockTwitsNinja
StockTwitsNinja Aug. 9 at 12:55 PM
$CERO My cost is 16.8 and I am looking to average down. Does anyone know of any upcoming events this year that could potentially drive the stock price higher?
3 · Reply
OldNag
OldNag Aug. 7 at 11:04 AM
$CERO Up,Up,Up...let's get er' done!!
0 · Reply
Radar76
Radar76 Aug. 7 at 1:15 AM
$CERO Maybe this starting point to wake up and move positively ! . . .
0 · Reply
OldNag
OldNag Aug. 6 at 12:13 PM
$CERO big day up today...wont stay single digits long.
1 · Reply
ChipPetey11
ChipPetey11 Aug. 5 at 3:26 PM
$CERO
0 · Reply
Iamparishilton
Iamparishilton Aug. 5 at 2:50 PM
$CERO back in
0 · Reply
Ultra_Calls
Ultra_Calls Aug. 5 at 2:05 PM
$CERO IN!!! Confidence trade! CAN DO 100% MOVE FAST just like $YMAB & $SMXT
0 · Reply
Putnik
Putnik Aug. 4 at 4:36 PM
$TNFA this reminds me of when $CERO was at .085 to .11 range then it went to .40 cents on news. This has a much lower OS than cero did so .50 can happen quick.
0 · Reply
Lauvier4
Lauvier4 Aug. 4 at 12:25 PM
$CERO
0 · Reply
JarvisFlow
JarvisFlow Aug. 4 at 12:00 PM
D. Boral Capital updates rating for CERo Therapeutics Hldgs ( $CERO ) to Buy, target set at 30.
0 · Reply